Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share purchase agreement with buyer Clayton Dubilier & Rice (CD&R).

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton Dublilier & Rice, known as CD&R. The two companies shared that they have ...

Bpifrance is expected to participate as a minority shareholder with a c.2% stake in Opella, with Sanofi remaining a significant shareholder. The terms of the transaction remain unchanged from ...

Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in ...

In October last year, the company had announced that it has entered into exclusive negotiations to sell the stake in Opella to CD&R. The valuation of Opella was then based on an enterprise value ...

Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in ...

Bpifrance is expected to participate as a minority shareholder with a c.2% stake in Opella, with Sanofi remaining a significant shareholder. The terms of the transaction remain unchanged from ...

It can also be filed by anyone who has made a distribution from a 529 plan, also known as a qualified tuition program (QTP). CESAs and QTPs are tax-advantaged investment accounts designed to pay ...

Opella is well-known in France for manufacturing the painkiller Doliprane. Image credit: Shutterstock / Leitenberger Photography. Sanofi’s sale of its $17bn consumer health business Opella just ...